Minoryx Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 32

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 12

Minoryx General Information

Description

Operator of a biotechnology platform intended to provide treatments for life-threatening rare diseases. The company's platform develops therapies focused on a group of diseases of genetic origin with unmet medical needs and discovers a new generation of pharmacological chaperones to restore protein functionality, enabling patients with therapy for the suffering of orphan diseases.

Contact Information

Website
www.minoryx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Avenida Ernest Lluch 32
  • 08302 Barcelona
  • Spain
+34 935
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Avenida Ernest Lluch 32
  • 08302 Barcelona
  • Spain
+34 935

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Minoryx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private Completed Generating Revenue
10. Later Stage VC (Series C) 31-May-2022 Completed Generating Revenue
9. Debt - General 16-Oct-2020 Completed Generating Revenue
8. Later Stage VC (Series B) 20-May-2020 Completed Generating Revenue
7. Grant 09-Apr-2018 Completed Generating Revenue
6. Later Stage VC (Series A) 25-Jul-2017 Completed Generating Revenue
5. Later Stage VC 15-Feb-2017 Completed Generating Revenue
4. Seed Round 23-Dec-2014 Completed Generating Revenue
3. Grant 06-Dec-2013 $6.76K $2.07M Completed Generating Revenue
2. Seed Round 02-Apr-2013 $2.07M $2.07M Completed Generating Revenue
To view Minoryx’s complete valuation and funding history, request access »

Minoryx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 31,735 $5.434702 $192.72 $192.72 $192.72 16.65%
Ordinary 12,441 $5.434702 $205.31 $205.31 $205.31 6.53%
To view Minoryx’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Minoryx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology platform intended to provide treatments for life-threatening rare diseases. The company's pl
Drug Discovery
Barcelona, Spain
32 As of 2026

South San Francisco, CA
 

Seattle, WA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Minoryx Competitors (106)

One of Minoryx’s 106 competitors is Maze Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Maze Therapeutics Formerly VC-backed South San Francisco, CA
Immusoft Venture Capital-Backed Seattle, WA
Lexeo Therapeutics Formerly VC-backed New York, NY
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
Orchard Therapeutics Formerly VC-backed London, United Kingdom
You’re viewing 5 of 106 competitors. Get the full list »

Minoryx Patents

Minoryx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024268104-A1 Polymorphic forms and formulations of leriglitazone Pending 09-May-2023
EP-4709476-A2 Polymorphic forms and formulations of leriglitazone Pending 09-May-2023
US-20260306468-A1 Polymorphic forms and formulations of leriglitazone Pending 09-May-2023
WO-2024231881-A2 Polymorphic forms and formulations of leriglitazone Inactive 09-May-2023
WO-2024231881-A3 Polymorphic forms and formulations of leriglitazone Inactive 09-May-2023 A61K47/10
To view Minoryx’s complete patent history, request access »

Minoryx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Minoryx Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
CDTI Innvierte Government Minority
Columbus Venture Partners Venture Capital Minority
Eurazeo Asset Manager Minority
Carbon ( Belgium ) Venture Capital Minority
Fund+ Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Minoryx FAQs

  • When was Minoryx founded?

    Minoryx was founded in 2011.

  • Where is Minoryx headquartered?

    Minoryx is headquartered in Barcelona, Spain.

  • What is the size of Minoryx?

    Minoryx has 32 total employees.

  • What industry is Minoryx in?

    Minoryx’s primary industry is Drug Discovery.

  • Is Minoryx a private or public company?

    Minoryx is a Private company.

  • What is Minoryx’s current revenue?

    The current revenue for Minoryx is .

  • How much funding has Minoryx raised over time?

    Minoryx has raised $140M.

  • Who are Minoryx’s investors?

    CDTI Innvierte, Columbus Venture Partners, Eurazeo, Carbon ( Belgium ), and Fund+ are 5 of 12 investors who have invested in Minoryx.

  • Who are Minoryx’s competitors?

    Maze Therapeutics, Immusoft, Lexeo Therapeutics, Aro Biotherapeutics, and Orchard Therapeutics are some of the 106 competitors of Minoryx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process